These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 11698709)
1. Drug-resistant mutants of HIV-1 in patients exhibiting increasing CD4 cell count despite virological failure of highly active antiretroviral therapy. Antinori A; Liuzzi G; Cingolani A; Bertoli A; Di Giambenedetto S; Trotta MP; Rizzo MG; Girardi E; De Luca A; Perno CF AIDS; 2001 Nov; 15(17):2325-7. PubMed ID: 11698709 [No Abstract] [Full Text] [Related]
2. Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy. Chiappini E; Galli L; Zazzi M; de Martino M J Med Virol; 2003 Aug; 70(4):506-12. PubMed ID: 12794711 [TBL] [Abstract][Full Text] [Related]
3. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes. Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628 [TBL] [Abstract][Full Text] [Related]
4. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. Hogg RS; Bangsberg DR; Lima VD; Alexander C; Bonner S; Yip B; Wood E; Dong WW; Montaner JS; Harrigan PR PLoS Med; 2006 Sep; 3(9):e356. PubMed ID: 16984218 [TBL] [Abstract][Full Text] [Related]
5. Discordant movement of CD4-positive T-cell count in HIV-1 infected patients with HAART failure. Okano A; Matsuda M; Chiba T; Moriya K; Yamada K; Sugiura W Jpn J Infect Dis; 2002 Apr; 55(2):62-5. PubMed ID: 12082315 [No Abstract] [Full Text] [Related]
6. Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure. Badri SM; Adeyemi OM; Max BE; Hota BN; Barker DE AIDS Patient Care STDS; 2007 Aug; 21(8):544-50. PubMed ID: 17711379 [TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy. Couto-Fernandez JC; Silva-de-Jesus C; Veloso VG; Rachid M; Gracie RS; Chequer-Fernandez SL; Oliveira SM; Arakaki-Sanchez D; Chequer PJ; Morgado MG Mem Inst Oswaldo Cruz; 2005 Feb; 100(1):73-8. PubMed ID: 15867968 [TBL] [Abstract][Full Text] [Related]
8. Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART. Røge BT; Katzenstein TL; Nielsen HL; Gerstoft J HIV Med; 2003 Jan; 4(1):38-47. PubMed ID: 12534958 [TBL] [Abstract][Full Text] [Related]
10. Analysis of HIV- type 1 protease and reverse transcriptase in Brazilian children failing highly active antiretroviral therapy (HAART). Machado DM; Fernandes SC; Succi RC; Freire WS; Pannuti CS; Gouveia AB; Levi JE; Diaz RS Rev Inst Med Trop Sao Paulo; 2005; 47(1):1-5. PubMed ID: 15729467 [TBL] [Abstract][Full Text] [Related]
11. Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire. Chaix ML; Rouet F; Kouakoussui KA; Laguide R; Fassinou P; Montcho C; Blanche S; Rouzioux C; Msellati P Pediatr Infect Dis J; 2005 Dec; 24(12):1072-6. PubMed ID: 16371868 [TBL] [Abstract][Full Text] [Related]
12. Genotypic drug resistance during HIV-1 primary infection in France (1996-1999): frequency and response to treatment. Harzic M; Pellegrin I; Deveau C; Chaix ML; Dubeaux B; Garrigue I; Ngo N; Rouzioux C; Goujard C; Hoen B; Sereni D; Delfraissy JF; Meyer L; AIDS; 2002 Mar; 16(5):793-6. PubMed ID: 11964538 [No Abstract] [Full Text] [Related]
13. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. Aleman S; Söderbärg K; Visco-Comandini U; Sitbon G; Sönnerborg A AIDS; 2002 May; 16(7):1039-44. PubMed ID: 11953470 [TBL] [Abstract][Full Text] [Related]
14. Antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the Northeast Region of Brazil. Cavalcanti AM; Lacerda HR; Brito AM; Pereira S; Medeiros D; Oliveira S Mem Inst Oswaldo Cruz; 2007 Nov; 102(7):785-92. PubMed ID: 17992369 [TBL] [Abstract][Full Text] [Related]
15. Study of antiretroviral mutants in HIV patients with treatment failures and the effect of risk factors in the virological failures. Taylor-Castillo L; Herrera-Martínez G; León-Bratti MP; Boza R; León-Rodríguez B; Luftig RB; Visoná K Rev Inst Med Trop Sao Paulo; 2005; 47(6):327-31. PubMed ID: 16553322 [TBL] [Abstract][Full Text] [Related]
16. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy. Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750 [TBL] [Abstract][Full Text] [Related]
17. Genotype testing and antiretroviral resistance profiles from HIV-1 patients experiencing therapeutic failure in northeast Brazil. Medeiros MS; Arruda EA; Guerrant RL; Brown C; Hammarskjold ML; Rekosh D; Lima AA Braz J Infect Dis; 2007 Aug; 11(4):390-4. PubMed ID: 17873990 [TBL] [Abstract][Full Text] [Related]
18. Drug resistance mutation profile and accumulation kinetics in human immunodeficiency virus-positive individuals infected with subtypes B and F failing highly active antiretroviral therapy are influenced by different viral codon usage patterns. Waléria-Aleixo A; Martins AN; Arruda MB; Brindeiro RM; Da-Silva RM; Nobre FF; Greco DB; Tanuri A Antimicrob Agents Chemother; 2008 Dec; 52(12):4497-502. PubMed ID: 18838582 [TBL] [Abstract][Full Text] [Related]
19. HIV-1 Drug Resistance Profiles for the HIV Protease and Reverse Transcriptase Gene in Patients Receiving Combination Therapy in Tehran, Iran. Sadeghi L; Lolaie M; Tabatabai RA; Bayanolhagh S; Taj L; Ahmadi NE; Abedinzadeh N; Vakili F; Ahmadi G; Mohraz M Infect Disord Drug Targets; 2018; 18(3):241-248. PubMed ID: 29663899 [TBL] [Abstract][Full Text] [Related]
20. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression. Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]